New research from Tokyo, Japan could help clarify the role of proinflammatory mediators in the pathogenesis of chronic inflammatory myopathies, such as polymyositis and dermatomyositis. Elevated ...

“Current arthritis treatment options include TNF blockers, the anti-IL-6 receptor antibody tocilizumab, the IL-1 blocker anakinra, and the CD28 costimulation blocker abatacept. An anti-CD70 ...